Format

Send to

Choose Destination
See comment in PubMed Commons below
Neurology. 2004 Apr 27;62(8):1405-7.

Ropinirole for restless legs syndrome: a placebo-controlled crossover trial.

Author information

1
Parkinson's Disease and Movement Disorders Center, Mayo Clinic Scottsdale, AZ 85259, USA. cadler@mayo.edu

Abstract

The authors performed a double-blind, placebo-controlled, crossover study of ropinirole (0.5 to 6.0 mg/day) for restless legs syndrome (RLS). The RLS Rating Scale score improved (p < 0.001) from a mean (SD) of 25 (7) during placebo treatment to 13 (12) during ropinirole treatment. Eight of the 22 patients had complete resolution of symptoms on ropinirole. Adverse events included nausea and dizziness. Ropinirole was effective and well tolerated for treating the symptoms of RLS.

PMID:
15111683
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for HighWire
    Loading ...
    Support Center